Conference LibraryGated
ESO-T01 · 9 patients in vivo BCMA CAR-T · r/r multiple myeloma · CRS in 4/5
在 5/16 抗体大会 Panel 3 上,panelist 讨论了 ESO-T01(EsoBiotec)的初步临床数据: - 总共描述 9 名 r/r multiple myeloma 患者 - 全部 9 名患者均成功在体内生成 CAR-T 细胞 - CAR-T 水平与 ex vivo delivery 相当 - 报告 vector infusion 后的 toxicity(不同于 ex vivo CAR-T) - CRS 出现在 CAR-T 注入后几天 - per Nature Medicine 2026 phase 1 报告:CRS in 4/5…
- Type
- evidence
- Domain
- oncology
- Grade
- conference
- License
- LIGHT_HOPE_proprietary
- Provenance
- m622_intel_seed_2026-05-16
- evidence_grade
- A
- category
- in_vivo_car_t_clinical_data
- status
- verified
- instance_tag
- sunvax-antibody-2025
- clinical_claim_softening
- "early IIT clinical data · feasibility demonstration · NOT validated late-stage clinical model · not intended to guide individual patient treatment choices"
- indication
- relapsed/refractory multiple myeloma (r/r MM)
- patient_count
- 9
- trial_id
- TBD · IIT trial in China per EsoBiotec PR 2024-12-11
- efficacy_summary
- 9/9 patients generated CAR-T cells in vivo · CAR-T levels similar to ex vivo delivery · extramedullary lesions eliminated · early efficacy signal · NOT validated late-stage outcome
- safety_summary
- CRS in 4/5 patients (3 grade 3) per Nature Medicine 2026 phase 1 report · 1 grade 1 ICANS · vector-infusion-related toxicity reported (different from ex vivo CAR-T) · NOT directly comparable to ex viv
Read-only aggregated view. Conference Library is the source of record; this catalog shows provenance as-is — no ratings, no reviews.